ReShape Lifesciences Inc. Common Stock
RSLS
RSLS was delisted on the 28th of December, 2018.
0 hedge funds and large institutions have $0 invested in ReShape Lifesciences Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $187K → $0 (-$187K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$187K |
RSLS Hedge Fund Activity: Q1 2019 in Review
0 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q1 2019, worth a combined $0 — down 100% from $187K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of RSLS and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, exiting entirely with an estimated $187K sold.
- 0 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q1 2019, down from 2 in Q4 2018.
- Funds reported $0 of ReShape Lifesciences Inc. Common Stock stock for Q1 2019, down 100% quarter-over-quarter.
- 0 funds opened new ReShape Lifesciences Inc. Common Stock positions in Q1 2019 and 2 closed out, a net change of -2 holders.
- The largest ReShape Lifesciences Inc. Common Stock seller in Q1 2019 was Sabby Management, an estimated $187K sold.
Based on aggregated 13F filings for Q1 2019.